XLONAGL
Market cap44mUSD
Jan 10, Last price
11.30GBP
1D
-3.83%
1Q
32.94%
Jan 2017
-76.82%
Name
Angle PLC
Chart & Performance
Profile
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers. The company was founded in 1994 and is based in Guildford, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑04 | 2018‑04 | 2017‑04 | 2016‑04 | 2015‑04 | |
Income | ||||||||||
Revenues | 2,186 109.99% | 1,041 2.76% | ||||||||
Cost of revenue | 12,476 | 5,473 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (10,290) | (4,432) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | (1,500) | (2,753) | ||||||||
Tax Rate | ||||||||||
NOPAT | (8,790) | (1,679) | ||||||||
Net income | (20,132) -7.17% | (21,686) 44.46% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 14 | 19,045 | ||||||||
BB yield | -0.05% | -15.29% | ||||||||
Debt | ||||||||||
Debt current | 649 | 662 | ||||||||
Long-term debt | 8,459 | 9,340 | ||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 396 | 216 | ||||||||
Net debt | (7,110) | (21,894) | ||||||||
Cash flow | ||||||||||
Cash from operating activities | (14,458) | (16,050) | ||||||||
CAPEX | (611) | (1,887) | ||||||||
Cash from investing activities | (203) | (1,751) | ||||||||
Cash from financing activities | (1,125) | 18,096 | ||||||||
FCF | (3,082) | (3,593) | ||||||||
Balance | ||||||||||
Cash | 16,218 | 31,896 | ||||||||
Long term investments | ||||||||||
Excess cash | 16,109 | 31,844 | ||||||||
Stockholders' equity | (92,979) | (75,753) | ||||||||
Invested Capital | 120,868 | 120,375 | ||||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 260,888 | 246,580 | ||||||||
Price | 0.12 -76.73% | 0.51 -57.56% | ||||||||
Market cap | 30,654 -75.38% | 124,523 -53.51% | ||||||||
EV | 23,544 | 102,629 | ||||||||
EBITDA | (8,463) | (1,594) | ||||||||
EV/EBITDA | ||||||||||
Interest | 325 | 368 | ||||||||
Interest/NOPBT |